IPHA (Innate Pharma S.A.) stock: $1.44, $160.8M market cap, $31.6M cash, $129.2M EV, $141.5M fully diluted market cap. Lead program: IPH5201 (Non Small Cell Lung Cancer), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
—Competition.” Risks Related to Regulatory Approval and Marketing of Innate's Product Candidates and Legal Compliance Matters Even if the Company completes the necessary preclinical and clinical studies, the marketing approval process is expensive, time-consuming and uncertain and may prevent the Company from obtaining approvals for the commercialization of some or all of its product candidates.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Metastatic Cancer; Metastatic Breast Cancer; Metastatic Pancreatic Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.